Hoth Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 27, 2026
RKTO$0.38-3.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of December 2025 and 2024
CONSOLIDATED BALANCE SHEETS
| December 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $6,247,467 | $7,038,923 |
| Prepaid expenses and other current assets | 366,548 | 605,948 |
| Crypto assets, at fair value | 191,367 | - |
| Deferred offering costs | 57,171 | - |
| Total Current Assets | 6,862,553 | 7,644,871 |
| NON-CURRENT ASSETS: | ||
| Prepaid expenses and other assets, net of current portion | 699,420 | - |
| Operating lease right-of-use asset, net | 4,652 | 31,075 |
| Investment in joint ventures at fair value | 36,819 | 36,819 |
| Total Non-Current Assets | 740,891 | 67,894 |
| Total Assets | $7,603,444 | $7,712,765 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES: | ||
| Accounts payable | $823,674 | $412,071 |
| Accrued expenses | 623,323 | 390,760 |
| Operating lease liability, current portion | 5,678 | 28,366 |
| Total Current Liabilities | 1,452,675 | 831,197 |
| LONG-TERM LIABILITIES: | ||
| Operating lease liability, less current portion | - | 2,709 |
| Total Long-Term Liabilities | - | 2,709 |
| Total Liabilities | 1,452,675 | 833,906 |
| Commitments and Contingencies (Note 6) | ||
| STOCKHOLDERS’ EQUITY: | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 3,000,000 shares undesignated; 0 shares issued and outstanding as of December 31, 2025 and 2024 | - | - |
| Series A Convertible Preferred Stock, $0.0001 par value; 5,000,000 shares designated; 0 shares issued and outstanding as of December 31, 2025 and 2024 | - | - |
| Series B Preferred Stock, $0.0001 par value; 2,000,000 shares designated; 0 shares issued and outstanding as of December 31, 2025 and 2024 | - | - |
| Common stock, $0.0001 par value; 50,000,000 shares authorized; 15,514,312 and 8,042,747 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 1,551 | 804 |
| Additional paid-in capital | 79,017,730 | 67,279,033 |
| Accumulated deficit | (72,879,343) | (60,410,041) |
| Accumulated other comprehensive income | 10,831 | 9,063 |
| Total Stockholders’ Equity | 6,150,769 | 6,878,859 |
| Total Liabilities and Stockholders’ Equity | $7,603,444 | $7,712,765 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.